EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome

Rosa López-Hidalgo, Raúl Ballestín, Lorena Lorenzo, Sandra Sánchez-Martí, José Miguel Blasco-Ibáñez, Carlos Crespo, Juan Nacher, Emilio Varea

Neurochemistry International · 2024-03 · 174 · 105679

DOI: 10.1016/j.neuint.2024.105679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurochemistry International, 2024-03. Verfasst von Rosa López-Hidalgo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Spain. Hauptthemen laut MEDLINE: Down Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Jérôme Lejeune, Jérôme Lejeune Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Down syndrome (DS) is the most common genetic disorder associated with intellectual disability. To study this syndrome, several mouse models have been developed. Among the most common is the Ts65Dn model, which mimics most of the alterations observed in DS. Ts65Dn mice, as humans with DS, show defects in the structure, density, and distribution of dendritic spines in the cerebral cortex and hippocampus. Fasudil is a potent inhibitor of the RhoA kinase pathway, which is involved in the formation and stabilization of dendritic spines. Our study analysed the effect of early chronic fasudil treatment on the alterations observed in the hippocampus of the Ts65Dn model. We observed that treating Ts65Dn mice with fasudil induced an increase in neural plasticity in the hippocampus: there was an increment in the expression of PSA-NCAM and BDNF, in the dendritic branching and spine density of granule neurons, as well as in cell proliferation and neurogenesis in the subgranular zone. Finally, the treatment reduced the unbalance between excitation and inhibition present in this model. Overall, early chronic treatment with fasudil increases cell plasticity and eliminates differences with euploid animals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeHumansMiceAnimalsMice, TransgenicHippocampusNeuronsDisease Models, AnimalMice, Inbred C57BL1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine

Stichwörter der Autor:innen

Balance excitation-inhibitionFasudilNeurogenesisSpine densityStructural plasticityTs65Dn

Substanzen

fasudil1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine

Autor:innen und Institutionen

  • Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Spain.
  • Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Spain; CIBERSAM, Spanish National Network for Research in Mental Health, Madrid, Spain; Institute of research of the Cl…
  • Neurobiology Unit, Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Spain. Electronic address: emilio.varea@uv.es.

Förderung

  • Fondation Jérôme Lejeune
  • Jérôme Lejeune Foundation

Zitieren

APA

López-Hidalgo, R., Ballestín, R., Lorenzo, L., Sánchez-Martí, S., Blasco-Ibáñez, J. M., Crespo, C., Nacher, J., & Varea, E. (2024). Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome. Neurochemistry International, 174, 105679. https://doi.org/10.1016/j.neuint.2024.105679

Vancouver

López-Hidalgo R, Ballestín R, Lorenzo L, Sánchez-Martí S, Blasco-Ibáñez JM, Crespo C, et al. Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome. Neurochemistry International. 2024;174:105679. doi:10.1016/j.neuint.2024.105679

BibTeX
@article{LpezHidalgo2024,
  author = {López-Hidalgo, Rosa and Ballestín, Raúl and Lorenzo, Lorena and Sánchez-Martí, Sandra and Blasco-Ibáñez, José Miguel and Crespo, Carlos and Nacher, Juan and Varea, Emilio},
  title = {Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome},
  journal = {Neurochemistry International},
  year = {2024},
  volume = {174},
  pages = {105679},
  doi = {10.1016/j.neuint.2024.105679}
}
Kostenlos starten →